APLS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
APLS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Apellis Pharmaceuticals's average Accounts Receivable for the three months ended in Sep. 2024 was $291.7 Mil. Apellis Pharmaceuticals's Revenue for the three months ended in Sep. 2024 was $196.8 Mil. Hence, Apellis Pharmaceuticals's Days Sales Outstanding for the three months ended in Sep. 2024 was 135.24.
The historical rank and industry rank for Apellis Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:
During the past 11 years, Apellis Pharmaceuticals's highest Days Sales Outstanding was 125.23. The lowest was 43.14. And the median was 55.40.
Apellis Pharmaceuticals's Days Sales Outstanding increased from Sep. 2023 (115.79) to Sep. 2024 (135.24).
Warning Sign:
If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.
The historical data trend for Apellis Pharmaceuticals's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apellis Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Days Sales Outstanding | Get a 7-Day Free Trial | - | - | 55.40 | 43.14 | 98.55 |
Apellis Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Days Sales Outstanding | Get a 7-Day Free Trial | 115.79 | 117.10 | 125.57 | 130.76 | 135.24 |
For the Biotechnology subindustry, Apellis Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Apellis Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Apellis Pharmaceuticals's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Apellis Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as
Days Sales Outstanding (A: Dec. 2023 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2022 ) | + | Accounts Receivable (A: Dec. 2023 )) | / | count ) | / | Revenue (A: Dec. 2023 ) | * | Days in Period |
= | ( (7.727 | + | 206.442) | / | 2 ) | / | 396.591 | * | 365 |
= | 107.0845 | / | 396.591 | * | 365 | ||||
= | 98.55 |
Apellis Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:
Days Sales Outstanding (Q: Sep. 2024 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Jun. 2024 ) | + | Accounts Receivable (A: Sep. 2024 )) | / | count ) | / | Revenue (A: Sep. 2024 ) | * | Days in Period |
= | ( (304.433 | + | 279.011) | / | 2 ) | / | 196.83 | * | 365 / 4 |
= | 291.722 | / | 196.83 | * | 365 / 4 | ||||
= | 135.24 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apellis Pharmaceuticals (NAS:APLS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of Apellis Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
James George Chopas | officer: See Remarks | 950 WINTER STREET, WALTHAM MA 02451 |
A. Sinclair Dunlop | director | C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Pascal Deschatelets | officer: Chief Operating Officer | 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Timothy Eugene Sullivan | officer: Chief Financial Officer | 800 BOYLSTON ST., SUITE 3310, PRUDENTIAL TOWER C/O AJU IB INVESTMENT, BOSTON MA 02199 |
Mark Jeffrey Delong | officer: Senior Vice President | 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451 |
Nur Nicholson | officer: Chief Technical Officer | APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451 |
Cedric Francois | director, 10 percent owner, officer: Chief Executive Officer | 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Adam J. Townsend | officer: See Remarks | C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
David O. Watson | officer: General Counsel | 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Karen Lewis | officer: Chief People Officer | APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451 |
Jeffrey Eisele | officer: See Remarks | APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451 |
Caroline Baumal | officer: Chief Medical Officer | C/O APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451 |
Lukas Scheibler | officer: See Remarks | C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Alec Machiels | director | 505 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10022 |
Federico Grossi | officer: See Remarks | C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
From GuruFocus
By GuruFocus News • 11-08-2024
By GlobeNewswire • 10-26-2024
By GuruFocus Research • 08-03-2024
By Marketwired • 10-26-2024
By Marketwired • 07-18-2024
By GuruFocus News • 11-22-2024
By Marketwired • 08-29-2024
By GuruFocus News • 11-04-2024
By Marketwired • 10-16-2024
By Marketwired • 09-25-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.